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Human adenoviruses are rarely associated with life-threatening infections in healthy individuals. How-
ever, immunocompromised patients, and particularly allogeneic hematopoietic stem cell transplant
recipients, are at high risk of developing disseminated and potentially fatal disease. The efﬁcacy of com-
monly used drugs to treat adenovirus infections (i.e., cidofovir in most cases) is limited, and alternative
treatment options are needed. Artiﬁcial microRNAs (amiRNAs) are a class of synthetic RNAs resembling
cellular miRNAs, and, similar to their natural relatives, can mediate the knockdown of endogenous gene
expression. This process, termed RNA interference, can be harnessed to target and potentially silence
both cellular and viral genes. In this study, we designed amiRNAs directed against adenoviral E1A,
DNA polymerase, and preterminal protein (pTP) mRNAs in order to inhibit adenoviral replication
in vitro. For the expression of amiRNA-encoding sequences, we utilized replication-deﬁcient adenoviral
vectors. In cells transduced with the recombinant vectors and infected with the wild-type (wt) adenovi-
rus, one particular amiRNA that was directed against the pTP mRNA was capable of decreasing the output
of infectious wt virus progeny by 2.6 orders of magnitude. This inhibition rate could be achieved by con-
catemerizing amiRNA-encoding sequences to allow for high intracellular amiRNA concentrations.
Because superinfecting wt virus induces the replication and ampliﬁcation of the recombinant adenoviral
vector, amiRNA concentrations were increased in cells infected with wt adenovirus. Furthermore, a com-
bination of amiRNA expression and treatment of infected cells with cidofovir resulted in additive effects
that manifested as a total reduction of infectious virus progeny by greater than 3 orders of magnitude.
 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Human adenoviruses (Echavarria, 2008; Ison, 2006; Kojaoghla-
nian et al., 2003), belonging to the group of double-stranded (ds)
DNA viruses, are a major cause of systemic infections with signiﬁ-
cant mortality rates in immunocompromised patients such as
hematopoietic stem cell transplant recipients (Blanke et al., 1995;
Hale et al., 1999; Howard et al., 1999; Lion et al., 2003; Munoz
et al., 1998). Severe manifestations are mostly caused by adenovi-
ruses belonging to species B and C (Kojaoghlanian et al., 2003), with
a predominance of species C members reported in certain studies
(Ebner et al., 2006; Lion et al., 2003, 2010). To date, the only drug
with convincing anti-adenoviral activity in vivo is cidofovir (CDV).
However, regarding the treatment of adenoviral infections in
immunocompromised patients, CDV is neither capable of fully pre-
venting fatal outcomes in all instances (Lenaerts et al., 2008; Linde-
mans et al., 2010; Ljungman et al., 2003; Symeonidis et al., 2007;
Yusuf et al., 2006), nor thought to be able to completely clear infec-
tions without the concomitant re-establishment of the immuneResearch Institute, Zimmer-
4490; fax: +43 1 40470 7437.
-NC-ND license. system (Chakrabarti et al., 2002; Heemskerk et al., 2005; Linde-
mans et al., 2010). Moreover, it displays signiﬁcant nephrotoxicity
and limited bioavailability. Derivatives of CDV have been devel-
oped, but are still under investigation (Hartline et al., 2005; Paolino
et al., 2011). Thus, there is a need for the development of alterna-
tive drugs or even alternative treatment strategies.
RNA interference (RNAi) is a post-transcriptional cellular pro-
cess that results in gene silencing (Carthew and Sontheimer,
2009; Ghildiyal and Zamore, 2009; Huntzinger and Izaurralde,
2011; Hutvagner and Simard, 2008; Kawamata and Tomari,
2010). It is triggered by short (21–25 nt) dsRNAs displaying par-
tial or complete complementarity to their target mRNAs (Fire et al.,
1998). MicroRNAs (miRNAs) are members of this group of small
RNAs. Their precursors, primary miRNAs (pri-miRNAs), are pro-
cessed by Drosha/DGCR8 into 60–70 nt precursor miRNAs (pre-
miRNAs) (Cullen, 2004), that are subsequently exported from the
nucleus by Exportin-5 (Yi et al., 2003), and eventually processed
into mature miRNAs by the ribonuclease-III enzyme Dicer (Cullen,
2004). The so-called guide strand is loaded into the RNA-induced
silencing complex (RISC) (Sontheimer, 2005), where it mediates
the cleavage or deadenylation of its target mRNA, or leads to trans-
lational repression (Huntzinger and Izaurralde, 2011).
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expression of disease-associated genes or to inhibit viral gene
expression (Davidson and McCray, 2011). This is either mediated
by synthetic short interfering RNAs (siRNAs) that are directly
incorporated into RISC (Elbashir et al., 2001), short hairpin shRNAs
that resemble pre-miRNAs (Burnett and Rossi, 2012), or artiﬁcial
miRNAs (amiRNAs) that are analogs of pri-miRNAs (Zeng et al.,
2002). RNAi-mediated inhibition of viral replication has been dem-
onstrated for a wide range of viruses, both in vitro and in vivo
(Arbuthnot, 2010; Haasnoot et al., 2007; Zhou and Rossi, 2011).
We and others have recently demonstrated the successful in vitro
inhibition of the replication of wild-type (wt) adenovirus (Ad) ser-
otypes 1, 2, 5, and 6 (all belonging to species C and representing a
main cause of severe adenovirus-related disease) (Kneidinger et al.,
2012) and a mutated version of Ad5 lacking the E1B and E3 genes
(Eckstein et al., 2010). The inhibition of an Ad 11 strain (2K2/507/
KNIH; species B; isolated in Korea) has also been described (Chung
et al., 2007). In all cases, inhibition of virus replication was medi-
ated by exogenously added siRNAs, and mRNAs originating from
viral genes directly or indirectly associated with viral DNA replica-
tion were identiﬁed as key targets (Kneidinger et al., 2012).
Although in vivo siRNA delivery has continuously been im-
proved over the last years (Rettig and Behlke, 2012), it still repre-
sents a major challenge. In particular, targeted delivery into certain
cell types or organs has proven tricky. In the past, viral vectors
have frequently and successfully been employed for the delivery
of protein-encoding DNA sequences into living organisms. Conse-
quently, they have also been adopted for the delivery of shRNAs
and amiRNAs (Liu and Berkhout, 2011; Mowa et al., 2010; Raoul
et al., 2006). Depending on the type of target cell, organ, or delivery
route, they may still outperform nonviral delivery systems in cer-
tain instances. Adenoviral vectors have been used for a long time
to deliver DNA sequences into living organisms (Goncalves and
de Vries, 2006). Since they display the same cell tropism as wt ade-
noviruses (when belonging to the same adenoviral species), they
deliver transgenic DNA into exactly those cells that represent the
main targets of their wt counterparts. Thus, adenoviral vectors
may constitute a particularly attractive tool for the delivery of
anti-adenoviral shRNAs or amiRNAs.
Consequently, in the present study, we generated a series of rep-
lication-deﬁcient adenoviral amiRNA expression vectors for the
silencing of selected Ad5 genes and investigated whether these
amiRNAs are capable of efﬁciently inhibiting the replication of wt
Ad5 upon transduction of a cell with the recombinant vector. The
amiRNAs were designed to recognize those mRNAs that had been
identiﬁed as candidate targets in our previous study (Kneidinger
et al., 2012), i.e., mRNAs encoding the viral E1A protein, a key regu-
lator of the infection cycle (Pelka et al., 2008), the preterminal pro-
tein (pTP), and the viral DNA polymerase, both essential for viral
DNA replication (de Jong et al., 2003). Here, we present data demon-
strating theefﬁcient silencingof thewtAd5pTPgeneupontransduc-
tionwith amiRNAexpression vectors.Moreover, wedemonstrate an
increase in the knockdown rate upon concatemerization of amiRNA-
encoding sequences, and we show that amiRNA expression is
strongly boosted in wt Ad5-infected cells, a prerequisite for the efﬁ-
cient targeting of high numbers of viral transcripts. Taken together,
our data indicate that amiRNA-mediated knockdownofwtAd5 gene
expression signiﬁcantly inhibits viralDNAreplicationandefﬁciently
decreases the output of infectious virus progeny in vitro.
2. Materials and methods
2.1. Cell culture, virus production, and titer determination
HEK 293 (human embryonic kidney; ATCC CRL-1573), A549
(human epithelial lung carcinoma; ATCC CCL-185), HeLa (humanepithelial carcinoma; ATCC CCL-2), SW480 (human colon carci-
noma; ATCC CCL-228), RD-ES (Ewing’s sarcoma; ATCC HTB-166),
and T-REx-293 cells (Life Technologies Austria, Vienna, Austria)
were cultivated in Dulbecco’s Modiﬁed Eagles Medium (DMEM)
with stabilized glutamine (PAA Laboratories, Pasching, Austria)
and supplemented with 10% fetal bovine serum (FBS; PAA Labora-
tories) in a humidiﬁed 5% CO2 atmosphere at 37 C. Recombinant
adenoviral vectors expressing Ad5-directed amiRNAs were ampli-
ﬁed in T-REx-293 cells. All other adenoviral vectors and wt Ad5
(ATCC VR-5) were ampliﬁed in HEK 293 cells. Titers of infectious
adenoviruses expressing amiRNAs were determined on T-REx-
293 cells by 50% tissue culture infective dose (TCID50) assays. Titers
of wt Ad5 present in mixed virus suspensions containing both wt
and recombinant virus as obtained in combined transduction/
infection experiments were determined on A549 cells using the
same method. All other TCID50 assays were performed with HEK
293 cells.
2.2. Vector constructions
The vectors employed in dual-luciferase assays for the screen-
ing of Ad5-directed amiRNAs have been described elsewhere
(Kneidinger et al., 2012). The dual-luciferase target vector used
for the determination of Renilla luciferase gene silencing in Ad5-in-
fected cells was constructed as follows: a part of the modiﬁed cod-
ing region of the ﬁreﬂy (Photinus pyralis) luciferase open reading
frame (ORF) representing the target sequence for the correspond-
ing amiRNA was ampliﬁed by PCR with primers Fluc-f2 (50-ATAA
GGCTATCTCGAGATACGCCCTGGTTCC-30) and Fluc-r2 (50-AATGT
CGTTCGCGGCCGCAACTGCAACTCCGAT-30) from vector pGL3 (Pro-
mega, Mannheim, Germany). This fragment was restricted with
XhoI and NotI and inserted into the corresponding sites located
within the 30UTR of the Renilla luciferase gene present on plasmid
psiCHECK-2 (Promega, Mannheim, Germany). From the resulting
vector (psiCHECK-FLuc2), a BglII-BamHI fragment comprising both
the ﬁreﬂy and Renilla luciferase expression cassettes was trans-
ferred into pENTR4 (Life Technologies Austria, Vienna, Austria) that
had been restricted with XmnI and EcoRV. From the resulting vec-
tor (pENTR-Luc), the entire expression cassette was eventually
moved into the deleted E1 region of the adenoviral vector pAd/
PL-DEST (Life Technologies Austria, Vienna, Austria) giving rise to
vector Ad-Luc-as (Fig. 1). This ﬁnal transfer was mediated by
employing Life Technologies’ Gateway technology, i.e., by site-spe-
ciﬁc recombination between sequences ﬂanking the expression
cassette on pENTR-Luc and the corresponding sequences located
on the adenoviral vector. The recombination reaction was per-
formed according to the instructions of the manufacturer (Life
Technologies Austria, Vienna, Austria). The adenoviral vector
expressing the amiRNA directed against the target sequence pres-
ent in the 30UTR of the Renilla gene on Ad-Luc-as was constructed
in a similar way by transferring the enhanced green ﬂuorescence
protein (EGFP)/amiRNA expression cassette of plasmid
pcDNA6.2-GW/EmGFP-miR-luc (Life Technologies Austria, Vienna,
Austria) into pAd/CMV/V5-DEST™ via site-speciﬁc recombination
as before. A corresponding adenoviral vector carrying a negative
control amiRNA cassette (originating from pcDNA6.2-GW/
EmGFP-miR-neg; Life Technologies Austria, Vienna, Austria) was
constructed analogously. The resulting adenoviral vectors were
named Ad-Fluc-mi1 and Ad-mi-, respectively (Fig. 1).
Construction of amiRNA expression vectors for the targeting of
adenoviral mRNAs: amiRNAs were designed using Life Technolo-
gie’s BLOCK-iT™ RNAi Designer and target site accessibility, as cal-
culated by RNAxs (http://rna.tbi.univie.ac.at/cgi-bin/RNAxs), was
taken into account. The annealed, double-stranded (ds), oligonu-
cleotides (Supplementary Table 1) supposed to give rise to pre-
miRNA hairpins (Fig. 2) contained 4 nucleotide (nt), 50 overhangs.
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Fig. 1. Schematic representation of adenoviral vectors. All vectors were based on the Ad5-derived vectors pAd/CMV/V5-DEST ™ or pAd/PL-DEST ™ (both from Life
Technologies) and lack the E1 and E3 genes. Expression cassettes were inserted into the deleted E1 region in sense or antisense orientation with respect to the left inverted
terminal repeat (ITR). Expression cassettes contained the indicated open reading frames (light grey) for ﬁreﬂy luciferase (F-Luc), Renilla luciferase (R-Luc), or enhanced green
ﬂuorescent protein (EGFP). The target sequence for amiRNA Luc-mi1 within the 30UTR of the Renilla luciferase gene is indicated by a small, dark grey box. Gene expression was
driven by the herpes simplex virus 1 thymidine kinase promoter (indicated as HSV), simian virus 40 early promoter (SV40), or cytomegalovirus promoter (CMV). Promoters
are indicated as boxed grey arrows. The 2 copies of tetracycline repressor-binding sequences are indicated as 2xTetO2. Mmu-miR-155-derived sequences ﬂanking the hairpins
that give rise to mature amiRNAs are indicated as small, dark grey boxes. Polyadenylation sequences are indicated as p(A).
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pre-cut plasmid vector pcDNA6.2-GW/EmGFP-miR (Life Technolo-gies Austria, Vienna, Austria) giving rise to amiRNA expression
vectors for E1A silencing (pmiRE-E1A-mi1 to -mi4), Ad5 DNA
Fig. 2. Predicted stem-loop structures giving rise to adenovirus-directed amiRNAs.
The amiRNAs were designed to target E1A-13S and E1A-12S mRNAs (E1A-mi1 to
E1A-mi4), DNA polymerase mRNA (Pol-mi1 to Pol-mi7), or pTP mRNA (pTP-mi1 to
pTP-mi5). All pre-amiRNAs were based on the murine mmu-miR-155 pre-miRNA
and contain 2-nt central mismatches. The sequences giving rise to the mature
antisense strands are underlined.
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(pmiRE-pTP-mi1 to -mi5). In these vectors, the pri-miRNAs are lo-
cated in the 30UTR of an EGFP gene. Both the EGFP gene and the pri-
mRNAs are co-expressed from a constitutive CMV promoter/en-
hancer. The analogous vector pcDNA6.2-GW/EmGFP-miR-neg (Life
Technologies Austria, Vienna, Austria) harboring a universal, nega-
tive control amiRNA in the 30UTR of the EGFP gene served as a neg-
ative control.
Concatemerization of amiRNA-encoding sequences: the frag-
ment supposed to be added to the existing copy of the amiRNA-
encoding sequence was excised from the respective pcDNA6.2-
GW/EmGFP-miR-based vector with SalI and BglII. The vector al-
ready harboring one copy was restricted with SalI and BamHI,
and the second copy was inserted into those sites. Further frag-
ments containing single copies or multiple copies were added anal-
ogously by excision/insertion using the same restriction enzymes.
Concatermerization of pTP-mi5- and the negative amiRNA-encod-
ing sequences gave rise to vectors pmiRE-pTP-mi5x2, pmiRE-pTP-
mi5x3, pmiRE-pTP-mi5x6 and pmiREx2, pmiREx3, pmiREx6,
respectively.
Construction of plasmid vectors for doxycycline-controlled
EGFP/amiRNA expression: this series of vectors is based on pENTR4
(Life Technologies Austria, Vienna, Austria) and contains a frag-
ment comprising a CMV promoter/enhancer followed by a 2xTetO2
tetracyclin repressor binding site, a multiple cloning site, and a
BGH poly(A) site between the XmnI and XhoI sites of the pENTR4
backbone. This fragment was obtained by PCR from pcDNA4/TO
(Life Technologies Austria, Vienna, Austria) using primers CMV-
TO-f1 (50-TTGCATTTCGAATCTGCTTAGGGTTAGG-30) and BGHpA-
r2 (50-CCCAGCGAATTCTTTCCGCCTCAGAAG-30). The BclI site lo-
cated between the promoter/operator region and the BGH poly(A)
site was subsequently used for the insertion of the individual
EGFP/miRNA cassettes. These cassettes were ampliﬁed from the
corresponding pcDNA6.2-GW/EmGFP-miR-based vectors lacking
the tetracyclin repressor binding sites by PCR using primers
pmiRE-f2 (50-CAAAAATGATCACTTTAAAACCATGGTGAGC-30) and
pmiRE-r2 (50- AAGCTGTGATCAGATATCTCGAGTGCGGC-30). The
resulting EGFP/miRNA expression vectors were termed pTO-mi-
(carrying the negative control miRNA), pTO-E1A-mi3 (carrying
amiRNA E1A-mi3), pTO-Pol-mi4 and pTO-Pol-mi7 (carrying the
DNA polymerase-targeting amiRNAs Pol-mi4 and Pol-mi7, respec-
tively), and pTO-pTP-mi5 (carrying the pTP-targeting amiRNA pTP-
mi5). Versions of pTO-mi- carrying 2, 3, or 6 copies of the negative
control miRNA-encoding sequence were generated in an analogous
way and were named pTO-mi-x2, pTO-mi-x3, and pTO-mi-x6. Ver-
sions of pTO-pTP-mi5 carrying 2, 3, or 6 copies of the pTP-mi5-
encoding sequence were termed pTO-pTP-mi5x2, pTO-pTP-
mi5x3, and pTO-pTP-mi5x6.
Construction of adenoviral amiRNA expression vectors: eventu-
ally, the expression cassettes present in the pENTR4-based plasmid
vectors were transferred into pAd/PL-DEST (Life Technologies Aus-
tria, Vienna, Austria) by site-speciﬁc recombination between se-
quences ﬂanking the expression cassette and the corresponding
respective sequences located on the adenoviral vector as described
above. All resulting adenoviral vectors are depicted in Fig. 1.
Restriction enzymes and DNA-modifying enzymes were purchased
from Fermentas (St. Leon-Rot, Germany) or New England Biolabs
(Frankfurt amMain, Germany). PCR reactions were performed with
Pwo DNA polymerase obtained from Roche Diagnostics (Vienna,
Austria) or PEQLAB (Erlangen, Germany).
2.3. Nucleic acid extraction
Circular plasmid DNA was extracted with an EasyPrep Pro Plas-
midMiniprep Kit (Biozym, Oldendorf, Germany), or a HiSpeed Plas-
mid Midi Kit (QIAGEN, Hilden, Germany). PCR products were
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Germany), and adenoviral DNA was isolated with a QIAamp DNA
Blood Mini Kit (QIAGEN, Hilden, Germany). Total RNA was
extracted using a standard acid phenol/choloroform method.
2.4. Dual-luciferase assays
For amiRNA screens 1.2e + 05 HEK 293 or 1e + 05 HeLa cells
were seeded into the wells of 96-well plates and reverse transfec-
ted with 100 ng of individual dual-luciferase reporter vectors and
200 ng of amiRNA expression vector using Lipofectamine 2000
(Life Technologies Austria, Vienna, Austria). For each well 0.5 ll
Lipofectamine 2000 was diluted with 24.5 lL OptiMEM medium
(Life Technologies Austria, Vienna, Austria), and after 5 min of
incubation, 25 lL diluted Lipofectamine 2000 was mixed with
25 lL of plasmid DNA diluted in OptiMEM. After 20 min of incuba-
tion, the mixes were pipetted directly into the wells of a 96-well
plate and freshly harvested cells were added. After 24 h of incuba-
tion, the medium was exchanged, and the cells were incubated for
another 24 h. Fireﬂy and Renilla luciferase activities were deter-
mined at 48 h post-transfection using the Dual-Glo luciferase assay
(Promega, Mannheim, Germany), according to the manufacturer’s
instructions. Luminescence was measured on a Wallac Victor
1420 Multilabel Counter (Perkin Elmer Austria, Brunn am Gebirge,
Austria). Knockdown rates were calculated by normalizing Renilla
luciferase activities to ﬁreﬂy luciferase activities, and comparing
dual-luciferase ratios between the targeting amiRNAs and the
non-targeting negative control amiRNA.
Knockdown experiments in which the ﬁreﬂy luciferase-speciﬁc
amiRNA was employed were performed as follows: 1.5e + 05 HEK
293 cells or 2e + 04 A549 cells were seeded into the wells of a
96-well plate. Twenty-four hours thereafter, the cells were trans-
duced with Ad-Luc-as at a multiplicity of infection (MOI) of 1
TCID50/cell and either Ad-FLuc-mi1 or Ad-mi-, each at an MOI of
10 TCID50/cell. In the case of A549 cells, the cells were additionally
infected with wt Ad5 at an MOI of 100 TCID50/cell. Alternatively,
2e + 04 A549, 1.6e + 05 HEK 293, 1.6e + 05 SW480, or 1e + 04 RD-
ES cells seeded into 96-well plates were infected with wt Ad5 at
an MOI of 100 TCID50/cell, and 1 h after infection, cells were co-
transfected with 100 ng of the target vector psiCHECK-FLuc2 and
increasing amounts (25–200 ng) of the amiRNA expression vector
pcDNA6.2-GW/EmGFP-miR-luc or its corresponding negative con-
trol vector pcDNA6.2-GW/EmGFP-miR-neg. Renilla luciferase activ-
ities in relation to ﬁreﬂy luciferase activities were determined 24
or 48 h post-infection as described above. Experiments in which
the effect of chaining of amiRNA-encoding sequences present on
plasmid vectors was investigated were carried out essentially in
the same way except that 50 ng of amiRNA expression vector
and 50 or 100 ng target vector was used for co-transfections. Anal-
ogous experiments with adenoviral vectors were carried out by
ﬁrst transfecting T-REx-293 cells with 100 ng of psiCHECK-pTP fol-
lowed by transduction with adenoviral miRNA expression vectors
at an MOI of 30 TCID50/cell and treatment of the cells with or with-
out 1 lg/ml doxycycline. Luciferase activities were determined
24 h post-infection as before.
2.5. Determination of amiRNA and mRNA levels
Total RNA was isolated from cells using a standard acid phenol/
chloroform extraction method and residual DNA was removed
with TURBO™ DNase (Life Technologies Austria, Vienna, Austria).
pTP-mi5 levels were determined with a custom-designed TaqMan
small RNA assay (proprietary to Life Technologies Austria, Vienna,
Austria) according to the instructions of the manufacturer. For the
quantitation of mRNAs, total RNA was ﬁrst revese transcribed
using the High Capacity cDNA Reverse Transcription Kit (Life Tech-nologies Austria, Vienna, Austria) and subsequently analyzed by
real-time quantitative PCR (qPCR) using a LightCycler 480 Probes
master mix (Roche Diagnostics, Vienna, Austria) and primer/probe
sets speciﬁc for GAPDH (GAPDH-f1 50-TGCACCACCAACTGCTTAGC-
30, GAPDH-r1 50-GGCATGGACTGTGGTCATGAG-30, GAPDH-p1
50-CCTGGCCAAGGTCATCCATGACAACTT-30), or Ad5 pTP (pTP-
cDNA-f2 50-AAACCAACGCTCGGTGCC-30, pTP-cDNA-r2 50-GG
ACGCGGTTCCAGATGTT-30, pTP-cDNA-p2 50-CGCGCGCAATCGTTGA
CGCT-30). All qPCRs were performed in duplicates on a LightCycler
480 platform (Roche Applied Science, Vienna, Austria).2.6. Virus replication experiments
3e + 04 A549 cells were seeded into the wells of a 96-well plate
and transduced with the recombinant adenoviruses at an MOI of
100 TCID50/cell. Twenty-four hours later, cells were infected with
wt Ad5 at an MOI of 0.01. If required, CDV was added to each well
in concentrations ranging from 0 to 30 lM. The plates were incu-
bated for 0, 2, 4, or 6 days without change of medium before freez-
ing at 80 C. Crude virus suspensions were obtained by freeze-
thawing the plates thrice and removal of cell debris by centrifuga-
tion for 15 min at 2800 rpm. The replication rate of recombinant
adenoviruses carrying different numbers of amiRNA-encoding se-
quences was assessed by infecting 1e + 05 T-REx-293 cells with
the vectors at an MOI of 0.1 TCID50/cell. AmiRNA expression was
induced by addition of 1 lg/ml doxycycline to the medium and
cells were allowed to grow for an additional 48 h. Crude lysates
were prepared as described above.2.7. Determination of adenovirus genome copy numbers
Wt Ad5 DNA levels were determined by qPCR using the follow-
ing TaqMan primer/probe set directed against the viral E1A gene
(E1A-fwd 50-GACGGCCCCCGAAGATC-30, E1A-rev 50-TCCTGCACC
GCCAACATT-30, and E1A-p 50-CGAGGAGGCGGTTTCGCAGA-30).
Adenovirus genome copy numbers were calculated by using serial
dilutions of an adenoviral reference DNA as a standard. DNA levels
of amiRNA-expressing recombinant viruses were determined using
a TaqMan primer/probe set speciﬁc for the adenoviral hexon gene
(hexon-fwd 50- CACTCATATTTCTTACATGCCCACTATT-30, hexon-rev
50- GGCCTGTTGGGCATAGATTG-30, hexon-probe 50- AGGAAGGTA
ACTCACGAGAACTAATGGGCCA -30). Otherwise, qPCR conditions
were as described above.2.8. FACS analysis
EGFP expression rates were determined by FACS analysis. Cells
transduced with EGFP-expressing adenoviruses were harvested by
trypsinization, resuspended in normal cell culture medium, and
pelleted by centrifugation at 1200 rpm for 5 min. Thereafter, cells
were washed once with phosphate buffered saline (PBS) and ﬁxed
with 1% formaldehyde in PBS. Samples were analyzed with a FACS
Calibur analyzer (Becton Dickinson, Heidelberg, Germany) and per-
centages of ﬂuorescent cells and mean ﬂuorescence intensities
(MFIs) were calculated.2.9. Statistical analysis
All the data are expressed as mean ± standard deviation (SD). To
test for statistical signiﬁcance, one-way ANOVA corrected with
Bonferroni’s post hoc test was applied. A p value of <0.05 was con-
sidered statistically signiﬁcant.
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3.1. Artiﬁcial miRNAs can mediate the knockdown of gene expression
in adenovirus-infected cells
At late stages of infection, adenoviruses produce high amounts
of the noncoding virus-associated RNAs (VA RNAs). These RNAs are
at least partially processed into functional miRNAs (mivaRNAs),
and their production has been reported to inhibit cellular RNAi
(Andersson et al., 2005; Lu and Cullen, 2004). This inhibition is
thought to be mediated by the saturation of the cellular RNAi
machinery at different levels (i.e., cleavage of pri-miRNAs by Dro-
sha, export of pre-miRNAs by Exportin-5, processing by Dicer,
and loading into RISC). Such an inhibition of RNAi in adenovirus-in-
fected cells may prevent successful knockdown of adenoviral gene
expression by adenovirus-targeting amiRNAs. Thus, we ﬁrst inves-
tigated whether expression of an amiRNA with proven activity at
reasonably high levels could mediate efﬁcient RNAi in adenovi-
rus-infected cells. We made use of a plasmid vector (pcDNA6.2-
GW/EmGFP-miR-luc) that produces an amiRNA from the 30UTR of
a transcript coding for EGFP. This amiRNA was directed against
the mRNA of the luciferase gene of a humanized ﬁreﬂy variant,
and the guide strand displayed 100% complementary to its target
sequence, thus leading to the cleavage of its target RNA in an siR-
NA-like fashion. A corresponding vector (pcDNA6.2-GW/EmGFP-
miR-neg) carrying a universal, non-targeting, negative control
miRNA was employed as well. We inserted the corresponding
luciferase miRNA target sequence into the 30UTR of a Renilla lucif-
erase gene located on a distinct plasmid vector which, for internal
normalization, also harbored a ﬁreﬂy luciferase gene (with a se-
quence distinct from the one against which the amiRNA was direc-
ted). This vector was named psiCHECK-FLuc2. Since our goal was to
deliver amiRNAs into target cells via adenoviral vectors, we moved
the expression cassettes for the targeting and non-targeting amiR-
NAs into the deleted E1 region of a replication-deﬁcient, Ad5-based
vector, giving rise to the adenoviral miRNA expression vectors Ad-
FLuc-mi1 and Ad-mi1-, respectively (Fig. 1). A corresponding aden-
oviral target vector (Ad-Luc-as; Fig. 1) carrying the dual-luciferase
expression cassette, which included the amiRNA target site, was
constructed in an analogous way.
When we co-transduced A549 cells with the adenoviral target
vector and its corresponding amiRNA expression vector, we ob-
served an efﬁcient knockdown of Renilla luciferase gene expression
(>90%) at 24 and 48 h after transduction when compared to the
artiﬁcial negative control miRNA vector. This knockdown rate
was not changed upon concomitant infection of the cells with high
numbers of wt Ad5 (MOI = 100; Fig. 3A). This high amount of wt
virus was chosen to assure high-level production of VA RNAs. We
repeated the experiments with HEK 293 cells and observed simi-
larly efﬁcient knockdown rates of approximately 90% (Fig. 3B). In
this experimental setting, infection with wt Ad5 was omitted be-
cause the presence of the E1 gene in the genome of HEK 293 cells
promotes the replication of replication-deﬁcient adenoviral vectors
in this cell line, consequently enhancing the production of high
amounts of VA RNAs in the absence of wt adenovirus. We also re-
peated the experiments in a slightly different way by expressing
the amiRNA and its target gene from their respective nonviral plas-
mid vectors in wt Ad5-infected A549, HEK 293, SW480, and RD-ES
cells and observed comparable knockdown rates (data not shown).
There was, however, a slight tendency (albeit not statistically sig-
niﬁcant in all cases) toward a slightly less pronounced knockdown
rate in A549 cells at 48 h post-infection in the presence of wt Ad5.
This effect likely reﬂected the observations made by Andersson
et al., (2005) and Lu and Cullen (2004). No such decrease in gene
expression knockdown was detectable at 24 h post-infection.In any case, the data indicated that it is feasible to efﬁciently
knock down the expression of a gene carried by a replicating ade-
novirus via an amiRNA provided by a second, co-infecting adenovi-
rus with no decrease in the knockdown rate at least at 24 and 48 h
post-infection. Considering that all amiRNAs we intended to design
were supposed to target early viral processes and should thus be
able to execute their functions, these results encouraged us to con-
tinue with the actual development of adenovirus-directed
amiRNAs.
3.2. Prevention of amiRNA expression in packaging cells
Adenovirus-directed amiRNAs, when expressed from adenoviral
vectors that carry the corresponding target sequence, would inev-
itably impair the ampliﬁcation of these vectors in packaging cells,
such as HEK 293 cells, consequently leading to poor virus titers.
Thus, we needed to assure that amiRNA expression is abolished
in these packaging cells. To this end, we generated an adenoviral
expression system in which the expression of amiRNAs (encoded
by sequences located in the 30UTR of the EGFP gene, as above) is
driven by a tetracycline (Tet) repressor-controlled CMV promoter
containing binding sites for 2 Tet repressor homodimers down-
stream of its TATA box. Thus, this promoter was repressed in cells
expressing the Tet repressor and active only in the presence of tet-
racycline or in cells lacking the repressor, such as the target cells
into which the vectors would be delivered.
This expression cassette was moved into the adenoviral vector
as before, and the adenoviral vectors were ampliﬁed and packaged
in T-REx-293 cells, a derivative of HEK 293 cells harboring the Tet
repressor. Since artiﬁcial pri-miRNAs are generated from longer
transcripts encoding EGFP in their 50 region, EGFP expression was
used as a measure for the repression of pri-miRNA expression in
the absence of doxycycline in T-REx-293 cells. FACS analysis of
EGFP expression revealed that transcription from the CMV pro-
moter is heavily reduced in the repressed state (i.e., in the absence
of doxycycline), as exempliﬁed for the adenoviral vector Ad-mi- in
Fig. 4. These data demonstrated that the controllable system was
also functional when incorporated into adenoviral vectors and
importantly, upon replication of these vectors. EGFP expression
from this viral vector-located expression cassette was high upon
addition of doxycycline, comparable to the expression rate typi-
cally achievable with analogous vectors containing a constitutively
active version of the CMV promoter (data not shown).
3.3. Construction of adenovirus-directed amiRNA expression vectors
All amiRNAs were designed to be ﬁrst expressed as pri-miRNAs
from the (nonviral) miRNA expression vector pcDNA6.2-GW/
EmGFP-miR. In this vector context, amiRNA hairpins are embedded
in the ﬂanking sequences of the murine mmu-miR-155 miRNA. The
pri-miRNA-encoding sequences are incorporated in the 30UTR of a
Renilla luciferase gene and are concomitantly expressed with the
EGFP gene from a common, constitutive CMV promoter. Ami-
RNA-containing transcripts can then be generated and processed
in the same way as naturally occurring pri-miRNAs/pre-miRNAs.
However, the inserted sequences were designed to match their tar-
get sequences completely and were therefore expected to lead to
the degradation of their target mRNAs.
Based on our results obtained with adenovirus-directed siRNAs,
we designed amiRNAs directed against E1A, DNA polymerase, and
pTP mRNAs of Ad5, which had previously been identiﬁed as prom-
ising targets (Kneidinger et al., 2012). For each target mRNA, at
least 4 different amiRNAs were designed (Fig. 2), and the respective
oligonucleotides containing the sequences of the pre-miRNA hair-
pins (Supplementary Table 1) were cloned into pcDNA 6.2-GW/
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Fig. 3. Artiﬁcial miRNA-mediated RNAi in cells infected with wt Ad5 or packaging cells promoting the replication of the adenoviral miRNA expression vectors. A. A549 cells
were co-transduced with the adenoviral target vector Ad-Luc-as carrying an miRNA target sequence in the 30UTR of a Renilla luciferase gene at an MOI of 1 TCID50/cell and the
adenoviral vector Ad-FLuc-mi1, which produces an amiRNA directed against the target sequence of the target vector at an MOI of 10 TCID50/cell. A corresponding adenoviral
vector (Ad-mi-) producing an artiﬁcial, non-targeting, amiRNA was used as a control. Concomitantly, cells were infected with wt Ad5 at an MOI of 100 TCID50/cell or were
mock-infected with wt Ad5. Renilla luciferase activities in relation to ﬁreﬂy luciferase activities were determined at 24 and 48 h post-infection. B. Co-infection of HEK 293
cells. Experimental set-up as in A, except that superinfection with wt Ad5 was omitted. Data represent relative light units (RLU; mean ± SD) in comparison to the non-
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Fig. 4. Expression of the EGFP/miRNA cassette from a tetracycline repressor-
controlled CMV promoter is heavily decreased in adenovirus packaging cells in the
absence of doxycycline. T-REx-293 cells were transduced with the adenoviral vector
AdTO- and incubated with or without doxycycline. Twenty-four hours later, the
cells were analyzed for EGFP expression by FACS analysis, and mean ﬂuorescence
intensities (MFIs) were calculated. Data represent the mean values of 3 independent
experiments, each performed in triplicate (mean ± SD; n = 3). ⁄⁄p < 0.01.
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E1A-mi1 to -mi4, pmiRE-Pol-mi1 to -mi7, and pmiRE-pTP-mi1 to
-mi5. A vector (pcDNA6.2-GW/EmGFP-miR-neg) encoding a uni-
versal, non-targeting amiRNA served as a reference for all other
amiRNA expression vectors, thus allowing for comparison between
groups of amiRNA expression vectors (i.e., amiRNA expression vec-
tors for the targeting of distinct adenoviral transcripts).
To select the most efﬁcient amiRNAs, we employed the same
dual-luciferase-based reporter system as described above. We ﬁrst
tested each group of amiRNAs (i.e., groups targeting either the E1A,
DNA polymerase, or pTP mRNAs) individually in combination with
reporter plasmid vectors harboring the respective target sequences
in the 30UTR of the Renilla luciferase mRNA (Fig. 5A–C). Finally, we
compared amiRNAs selected from each group (i.e., E1A-mi3, Pol-
mi4 and Pol-mi7, and pTP-mi5) side-by-side (Fig. 5D). The ob-
tained knockdown rates were similar for all selected amiRNAs. Be-
cause the transfection rates were well below 100% in these
experiments (but were identical for different vectors), as deter-
mined by parallel FACS experiments in which EGFP expression
was measured (data not shown), the absolute knockdown rates
were rather low. Thus, the knockdown rates observed in these
experiments did not reﬂect the true capacities of the tested amiR-NAs. For targeting of the DNA polymerase mRNA, we selected 2
distinct amiRNAs: Pol-mi7, which showed the highest knockdown
rate, and Pol-mi4, which performed slightly worse, but contained
the same seed sequence as Pol-si2, the most potent siRNA identi-
ﬁed through our previous study (Kneidinger et al., 2012).
Next, we modiﬁed the expression system of the selected vectors
by bringing the EGFP/amiRNA cassettes under the control of the
tetracycline repressor-regulated CMV promoter and subsequently
transferred these expression cassettes into the deleted E1 region
of the Ad5-based replication-deﬁcient adenoviral vector already
employed for the experiments described in Section 3.1. The result-
ing adenoviral vectors AdTO-mi-, AdTO-E1A-mi3, AdTO-Pol-mi4,
AdTO-Pol-mi7, and AdTO-pTP-mi5 are depicted in Fig. 1.
Since the dual-luciferase assay system represents an artiﬁcial
set-up, the efﬁcacy of amiRNAs must be properly evaluated in
the biological context. To this end, we transduced T-REx-293 cells
(which propagate the replication of otherwise replication-deﬁcient
adenoviral vectors lacking the E1 genes) with the individual aden-
oviral amiRNA expression vectors. The cells were cultivated in the
presence of doxycycline to allow for amiRNA expression, which, in
turn, was expected to lead to the attenuation of viral DNA replica-
tion in cases of highly efﬁcient amiRNAs. Finally, we determined
viral genome copy numbers for the time point 2 days post-infec-
tion by real-time qPCR using a primer/probe set directed against
the adenoviral hexon gene. As shown in Fig. 6, expression of
E1A-mi3, Pol-mi4, and Pol-mi7 did not cause a signiﬁcant reduc-
tion in viral genome copy numbers. The only amiRNA that was able
to decrease the ampliﬁcation of its own vector signiﬁcantly was
pTP-mi5. In this case, the copy number of the vector was decreased
to 26.9%. Thus, we selected the pTP-mi5 expression vector for fur-
ther optimization.
3.4. Concatemerization of pTP-mi5-encoding sequences increases
pTP-mi5 levels
It has been reported that expression of shRNA or amiRNA hair-
pins as tandem copies can enhance knockdown efﬁcacies (Chung
et al., 2006; Wu et al., 2011). Consequently, we generated vectors
in which the pTP-mi5 pre-mRNA hairpins were concatemerized.
We ﬁrst constructed additional pcDNA 6.2-GW/EmGFP-miR-based
plasmid vectors containing 2, 3, or 6 copies of pTP-mi5-encoding
sequences in the 30UTR of the EGFP gene (vectors pmiRE-pTP-
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Fig. 5. Screening for functional amiRNAs. Plasmid-based amiRNA expression vectors and their respective dual-luciferase target vectors were used to cotransfect HeLa cells (A,
D) or HEK293 cells (B, C). Each group of artiﬁcial miRNAs, i.e., those directed against E1A (A), DNA polymerase (B), or pTP (C) target sequences, were ﬁrst evaluated
individually, and selected candidates were eventually evaluated side-by-side in a second round (D) by determining Renilla luciferase activities in relation to ﬁreﬂy luciferase
activities. A plasmid vector expressing a universal non-targeting amiRNA served as a negative control (neg. ctrl.) in all experiments. Relative light units (RLU; mean ± SD,
n = 3) in comparison to the non-targeting artiﬁcial control miRNA are shown. ⁄⁄⁄p < 0.001; ns: not signiﬁcant.
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Fig. 6. Replication of adenoviral amiRNA expression vectors is inhibited in
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Fold-increases of vector copy numbers were calculated for all vectors. Data
represent the means ± SD of 3 independent experiments, each performed in
triplicate. ⁄p < 0.05.
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tive negative control vectors carrying a corresponding number of
negative control amiRNA hairpins (vectors pmiREx2, pmiREx3,
and pmiREx6). Transfection of HEK 293 cells with pTP-mi5-encod-ing vectors revealed that the amount of mature pTP-mi5 increased
with rising copy numbers in the constructs (Fig. 7A). The gain in
the amount of pTP-mi5 present in the cells ranged from 6.8-fold
(2 copies) to 20.3-fold (6 copies). Not surprisingly, there was an in-
verse correlation with EGFP expression: increased numbers of hair-
pins present in the 30UTR of the EGFP gene led to decreased EGFP
levels (Fig. 7B). This effect was not only evident for the pTP-mi5-
encoding constructs but also for constructs encoding the negative
control amiRNA. The observed decrease was likely due to enhanced
processing of the primary transcripts by Drosha with increased
amiRNA hairpin copy numbers, accelerated degradation of the pro-
cessed forms due to lack of a 30 poly(A) tail after Drosha cleavage,
or decreased translation.
3.5. Concatemerization of pTP-mi5-encoding sequences increases the
knockdown rate
To determine whether elevated levels of pTP-mi5 produced by
pmiRE-pTP-mi5x6 in comparison to pmiRE-pTP-mi5 had a positive
effect on the knockdown rate, we performed dual-luciferase-based
knockdown experiments as before. Knockdown of Renilla luciferase
expression in HEK 293 cells transfected with the target vector psi-
CHECK-pTP was signiﬁcantly increased upon raising the copy num-
ber of pTP-mi5 from 1 to 6 (Fig. 8A), revealing the expected
positive correlation between amiRNA levels and knockdown
capacities.
Next, we modiﬁed these plasmid vectors by replacing the
constitutive CMV promoter with the tetracycline-regulated CMV
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Fig. 7. Concatemerization of amiRNA-encoding sequences increases amiRNA levels and decreases EGFP expression. HEK293 cells were transfected with identical amounts of
plasmid expression vectors carrying 1–6 copies of pTP-mi5 (i.e., vectors pmiRE-pTP-mi5, pmiRE-pTP-mi5x2, pmiRE-pTP-mi5x3, and pmiRE-pTP-mi5x6) or the corresponding
negative control amiRNA (i.e., vectors pcDNA6.2-GW/EmGFP-miR-neg, pmiREx2, pmiREx3, and pmiREx6) in the 30UTR of the EGFP gene. Forty-eight hours after transfection,
pTP-mi5 levels were measured by RT-qPCR (A), and EGFP expression was determined by FACS analysis (B). Means of relative pTP-mi5 levels and mean ﬂuorescent intensities
(MFIs) from 3 independent transfections (mean ± SD, n = 3) are shown. ⁄p < 0.05, ⁄⁄p < 0.01, ns: not signiﬁcant.
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into adenoviral vectors as before. The ﬁnal set of adenoviral vectors
(Fig. 1) contained 1, 2, 3, or 6 copies of the pTP-mi5-encoding se-
quence (vectors AdTO-pTP-mi5, AdTO-pTP-mi5x2, AdTO-pTP-
mi5x3, and AdTO-pTP-mi5x6), or a corresponding number of cop-
ies of the sequence encoding the negative control amiRNA (vectors
AdTO-mi-, AdTO-mi-x2, AdTO-mi-x3, and AdTO-mi-x6). We evalu-
ated this set of vectors by again performing dual-luciferase assays;
brieﬂy, we transfected T-REx-293 cells with the pTP-mi5 target
vector psiCHECK-pTP and subsequently transduced those cells
with the adenoviral vectors at an MOI of 30 TCID50/cell. The cells
were cultivated in the presence of doxycycline for an additional
24 h to allow for the expression of amiRNA before determining
luciferase activities. As shown in Fig. 8B, Renilla luciferase expres-
sion showed a steady decrease with increasing copy numbers of
pTP-mi5-encoding sequences present on the vectors. This indi-
cated that the amiRNA expression cassette giving rise to highest
number of pTP-mi5 hairpins was the most effective when incorpo-
rated into the adenoviral vector backbone.
The positive effect of incorporating 6 copies of pTP-mi5 hairpins
was also reﬂected by the increased inhibition of viral vector ampli-
ﬁcation in T-REx-293 cells when the cells were cultivated in the
presence of doxycycline, i.e., upon derepression of EGFP and pTP-
mi5 expression (Fig. 9). No such effect was observed for vectors
encoding the negative control amiRNA, indicating that the de-
crease in vector copy number was speciﬁcally related to pTP-mi5
expression and not to the treatment of the cells with doxycycline.
Viral DNA synthesis was decreased by 0.9 orders of magnitude
(86.2%) for the vector containing 1 copy of the pTP-mi5 hairpin.
There was no signiﬁcant difference in the inhibition rate when
the copy number was raised to 2 or 3. However, doubling the copy
number further from 3 to 6 generated a markedly increased inhib-
itory effect on vector ampliﬁcation. Here, viral DNA synthesis was
decreased by 1.6 orders of magnitude (97.6%) compared to the neg-
ative control vector. We also monitored the ampliﬁcation kinetics
of the vector containing 6 copies of the pTP-mi5-encoding se-
quence over a 6-day period and found a pronounced decrease in
vector copy numbers also at later time points in the presence of
doxycycline (Supplementary Fig. 1).
Because all experiments clearly suggested that chaining of pTP-
mi5 hairpins was a prerequisite for the successful inhibition of
adenovirus replication, all subsequent experiments were per-
formed with the vector carrying 6 copies of pTP-mi5.3.6. Levels of amiRNAs, when expressed from a replication-deﬁcient
adenoviral vector, are increased in wt adenovirus-infected cells
Replication-deﬁcient adenoviral vectors were chosen for the
expression of amiRNAs based on the assumption that net levels
of amiRNA should increase upon exposure of the recombinant vec-
tor to wt adenovirus in infected cells. Provided the amiRNA was
not capable of completely blocking viral DNA replication, amiRNA
gene copy numbers should increase upon onset of replication of
the recombinant vector, which should be induced by E1A gener-
ated by the co-infecting wt adenovirus. Indeed, we found pTP-
mi5 levels increased by 6-fold in A549 cells infected with wt
Ad5 (Fig. 10A).
To determine whether and to what extent pTP-mi5 inhibited
the expression of pTP during virus replication, we transduced
A549 cells with the adenoviral pTP-mi5 expression vector AdTO-
pTP-mi5x6 or its corresponding negative control amiRNA expres-
sion vector AdTO-mi-x6. Subsequently, we infected the cells with
wt Ad5 and determined pTP mRNA levels at 24 h post-infection
with wt Ad5 by RT-qPCR. As shown in Fig. 10B, pTP-mi5 expression
decreased pTP mRNA levels by nearly 80% compared to the nega-
tive control amiRNA.
3.7. Adenoviral vector-based expression of pTP-mi5 inhibits the
replication of wt Ad5
To ﬁnally investigate whether pTP-mi5 was capable of inhibit-
ing the replication of wt Ad5, we transduced A549 cells with
AdTO-pTP-mi5x6 or the negative control vector AdTO-mi-x6 and
infected themwith wt Ad5. To assure that all cells were transduced
with the recombinant vectors, we used rather high MOIs of 100
TCID50/cell and transduced the cells with the recombinant vectors
24 h prior to infection with wt Ad5. Wt Ad5 genome copy numbers
were determined at 0, 2, 4, and 6 days post-infection by real-time
qPCR using a primer/probe set directed against a part of the E1A
gene. As shown in Fig. 11A, wt Ad5 DNA levels were decreased
by 1.24, 1.21, and 1.77 orders of magnitude (94.2%, 93.8%, and
98.4%) on days 2, 4, and 6, respectively, in cells expressing pTP-
mi5, as compared to cells expressing the negative control amiRNA.
The negative control amiRNA itself did not signiﬁcantly inhibit wt
Ad5 replication.
As a consequence of the inhibition of viral DNA synthesis, the
generation of infectious wt Ad5 progeny was also heavily inhibited.
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Fig. 8. Concatemerization of pTP-mi5 hairpins increases the knockdown rate. A.
HEK 293 cells were transfected with 50 ng of the plasmid vectors pmiRE-pTP-mi5
and pmiRE-pTP-mi5x6 carrying 1 or 6 copies of the sequence encoding pTP-mi5,
respectively, and either 50 or 100 ng of the dual-luciferase reporter vector
psiCHECK-pTP harboring the target sequence of pTP-mi5. The vectors pmiRE and
pmiREx6, carrying 1 or 6 copies of a sequence encoding the non-targeting amiRNA,
served as negative controls (neg. ctrl.). Numbers of hairpins for amiRNAs in the
individual vectors are indicated as 1 x and 6 x, respectively. Renilla luciferase
activities in relation to ﬁreﬂy luciferase activities were determined 24 h post-
transfection. Relative light units (RLU) obtained with the vectors carrying pTP-mi5
in relation to their respective negative control vectors are shown. Data represent
the means ± SD of 2 independent experiments, each performed in triplicate. B. HEK
293 cells were transfected with 100 ng of psiCHECK-pTP. Twenty-four hours after
transfection, the cells were transduced with the adenoviral vectors AdTO-pTP-mi5,
AdTO-pTP-mi5x2, AdTO-pTP-mi5x3, or AdTO-pTP-mi5x6 expressing pTP-mi5 or
AdTO-mi-, AdTO-mi-x2, AdTO-mi-x3, or AdTO-mi-x6 expressing the negative
control amiRNA at an MOI of 30 TCID50/cell. The copy number of the amiRNA
hairpins is indicated beneath the ﬁgure. Renilla luciferase activities in relation to
ﬁreﬂy luciferase activities were determined 24 h post-infection. Relative light units
(RLU) obtained with the vectors carrying pTP-mi5 in relation to their respective
negative control vectors are shown. Data represent the means ± SD of 2 indepen-
dent experiments, each performed in triplicate. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ns:
not signiﬁcant.
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analysis using A549 cells as indicator cells (which permitted the
speciﬁc detection of wt Ad5 replication) was decreased by 2.6 or-
ders of magnitude (99.8%) in cultures transduced with the pTP-
mi5-expressing vector compared to control cultures expressing
the negative control amiRNA (Fig. 11B).
The amiRNA-mediated inhibitory effect on wt Ad5 DNA replica-
tion was also revealed when the cells were infected with wt Ad5 at
higher MOIs of up to 100 TCID50/cell (Supplementary Fig. 2). No
differences were observed for MOIs ranging between 0.01 and 1
(Supplementary Fig. 2A–C). At higher MOIs of 10 and 100 (Supple-
mentary Fig. 2D and E) there was a tendency toward a decrease in
the difference between wt Ad5 genome copy numbers of cellstransduced with the pTP-mi5 amiRNA expession vector and its
negative control vector. However, this decrease was not due to a
diminished inhibition of wt Ad5 DNA replication by the amiRNA,
because the slope from day 0 to day 2 was comparable for pTP-
mi5-expressing cells regardsless of which MOI was used for wt
Ad5 infection. The observed effect was rather due to a decrease
in the gain of wt Ad5 DNA from day 0 to day 2 when cells were in-
fected with wt Ad5 at high MOIs (compare slopes for cells not
transduced with any recombinant vector or with the amiRNA con-
trol vector at different MOIs).
The inhibitory effect described above was revealed with cells
that had been transduced with the recombinant amiRNA expres-
sion vector 24 h prior to infection with wt Ad5. However, an inhib-
itory effect on wt Ad5 replication was also observed when cells
were transduced with the pTP-mi5 expression vector only 6 h prior
to, concomitant with, or 6 h after infection with wt Ad5 (Supple-
mentary Fig. 3). Wt Ad5 replication was inhibited at all MOIs. How-
ever, we observed a tendency toward a slightly decreased
inhibition rate when cells were infected with wt Ad5 prior to trans-
duction with the recombinant vectors and when low MOIs were
used for wt Ad5 infection (compare slopes for cells transduced
with the pTP-mi5 expression vector in panels A, B, and C at wt
Ad5 MOIs of 0.01–1).3.8. AmiRNA expression and concomitant treatment with CDV results
in an additive inhibitory effect
The inhibitory effect of pTP-mi5 when expressed from and
delivered with a replication-deﬁcient adenoviral vector was very
pronounced, but not complete. Thus, we investigated whether
knockdown of pTP expression by pTP-mi5 and concomitant treat-
ment of infected cells with CDV may result in additive inhibitory
effects. To this end, we transduced and infected A549 cells as be-
fore and treated themwith therapeutically relevant concentrations
of CDV. The highest dose of CDV (30 lM) corresponded to in vivo
peak serum concentrations typically measured after intravenous
administration (Cundy, 1999). We assessed the inhibition of wt
Ad5 replication by determining wt Ad5 genome copy numbers at
time points 2 and 6 days post-infection (Fig. 12A and B). In our
experimental setting, adenoviral vector-mediated expression of
pTP-mi5 was generally more effective in inhibiting wt Ad5 replica-
tion than was treatment with CDV. However, the inhibitory effect
of pTP-mi5 could clearly be further increased by concomitant
treatment of the cells with CDV. pTP-mi5 expression alone de-
creased wt Ad5 genome copy numbers by 1.2 orders of magnitude
(94.2%) at day 2 post-infection and by 1.8 orders of magnitude
(98.4%) at day 6 post-infection when compared to the negative
control amiRNA. However, concomitant treatment of the cells with
30 lM CDV decreased wt Ad5 genome copy numbers by 2.2 orders
of magnitude (99.3%) at day 2 and by 2.5 orders of magnitude
(99.7%) at day 6. This clear additive effect also manifested as a fur-
ther drop in the output of infectious virus progeny (Fig. 12C); con-
comitant treatment with 30 lM CDV decreased the titer of wt Ad5
by another 0.6 orders of magnitude and resulted in a total reduc-
tion rate of 3.2 orders of magnitude (99.9%).4. Discussion
In contrast to anti-adenoviral siRNAs such as the ones used in
our previous study (Kneidinger et al., 2012), the generation of
anti-adenoviral amiRNAs is dependent on intracellular processing
steps which may be disturbed in adenovirus-infected cells due to
the saturation of several components of the RNAi pathway by
mivaRNAs (Andersson et al., 2005; Lu and Cullen, 2004). We
estimated the performance of amiRNAs during the ﬁrst 48 h of
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20 M. Ibrišimovic´ et al. / Antiviral Research 97 (2013) 10–23adenovirus infection as being especially critical, because viral DNA
replication – the viral process which we intended to target – lar-
gely takes place within this time frame. However, we found that
amiRNA function was not affected during these stages of adenovi-
rus infection when the amiRNA was delivered via an adenoviral
vector (Fig. 3). This is likely due to the fact that mivaRNAs reach
high levels only at very late stages of infection, and pTP mRNA-tar-geting amiRNAs prevent the otherwise steady increase in VA-RNA
gene copy numbers after the onset of viral DNA replication.
The design of amiRNAs follows slightly different rules compared
to those required for the design of 25-nt-long, blunt-ended siRNAs.
Although we designed certain amiRNAs (i.e., pTP-mi5 and Pol-mi4)
to contain the same seed sequences as their successful siRNA rela-
tives used in our previous study (Kneidinger et al., 2012), these
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(see Pol-mi4), indicating that it was not always feasible to auto-
matically convert an effective siRNA into a potent amiRNA. This
may be due to the different lengths of amiRNAs and siRNAs, their
different types of ends (i.e., blunt ends in the case of siRNAs and
2-nt 30 overhangs in the case of amiRNAs), and the lack of any
chemical modiﬁcations within amiRNAs.
Concatemerization of identical amiRNA-encoding sequences
has been shown to increase knockdown rates (Chung et al., 2006;
Wu et al., 2011). Consequently, we concatemerized pTP-mi5-
encoding sequences to increase the inhibition of adenoviral repli-
cation. While inhibition of the replication of the vector carrying
the pTP-mi5 expression cassette was limited to 0.9 orders of mag-
nitude (86.2%) when only one copy was present, increasing the
copy number from 1 to 6 resulted in a decrease of viral genome
copy number by 1.6 orders of magnitude (97.6%; Fig. 9). This effect
correlated with an increase in pTP-mi5 levels (Fig. 7A). However,
the increase in the amount of mature amiRNA was disproportion-
ally higher compared to the increase in the number of hairpins
present on primary transcripts. This effect may be related to an1E+01
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22 M. Ibrišimovic´ et al. / Antiviral Research 97 (2013) 10–23observation made byothers when placing a pre-amiRNA hairpin
onto a miRNA polycistron: when combined with other amiRNA
hairpins, the silencing capacity of the individual amiRNA was in-
creased (Liu et al., 2008).
Expression of pTP-mi5 from the adenoviral vector inhibited the
replication of superinfecting wt Ad5 by approximately 1.2 orders of
magnitude (94%) at 2 days post-infection with wt Ad5. This inhib-
itory effect was also evident by the suppression of infectious wt
Ad5 progeny output by 2.6 orders of magnitude (99.8%). Although
we used a low MOI of 0.01 TCID50/cell for wt Ad5 in most exper-
iments to allow for monitoring of virus spreading within the cul-
tures, the high burst size of adenovirus quickly led to infection of
the entire culture. Consequently, the exponential increase in virus
multiplication at later time points was disproportionately pre-
vented in cultures in which replication was not attenuated by
amiRNAs. Thus, regardless of the readout system, the pTP-mi5-
mediated inhibition rate at late time points (4 or 6 days post-infec-
tion) is probably underestimated.
Both CDV and pTP-mi5 target the same viral process, namely
viral DNA replication. However, while pTP-mi5 decreases the num-
ber of functional protein complexes that have to be formed for efﬁ-
cient initiation of viral DNA synthesis, CDV, as a nucleoside analog,
acts downstream of this step by preventing DNA polymerization
(Cundy, 1999). Thus, it was conceivable that a combination of both
mechanisms may result in additive inhibitory effects; while pTP-
mi5 would in a ﬁrst step limit the number of available DNA repli-
cation complexes, CDV would in a second step inhibit residual DNA
synthesis that could not be prevented by the amiRNA. Indeed, a
combination of pTP-mi5 expression and treatment with CDV re-
sulted in a further decrease of wt Ad5 genome copy numbers
and infectious virus progeny by an additional 1 and 0.6 orders of
magnitude, respectively, at 2 days post-infection with wt Ad5
(Fig. 12A and C).
The delivery of amiRNAs, shRNAs, or siRNAs into living organ-
isms is a challenging task. Based on the development of a plethora
of different delivery vehicles, nonviral delivery methods have con-
stantly been improved but are still far from perfect (Rettig and
Behlke, 2012). In this regard, the delivery of anti-adenoviral amiR-
NAs, via a replication-deﬁcient adenoviral vector, may have several
unique advantages. For example, it may allow for the ampliﬁcation
of amiRNA expression cassette copy numbers upon exposure of the
recombinant virus to the wt virus as demonstrated in our in vitro
experiments (Fig. 10) and theoretically ensure a constant supply
of recombinant vector as long as wt adenovirus is present. More-
over, based on the shared organ tropism of the adenoviral vector
and its wt counterpart, this type of delivery may also permit the
directing of amiRNAs predominantly to those cells that are also
the preferred targets of the wt virus.
It may be argued that treating a virus infection with a vector de-
rived from the very same virus may generally be dangerous. For
example, recombination events between the wt virus and the re-
combinant virus are conceivable, which may result in the genera-
tion of a replication competent virus. This potential problem
could generally be circumvented by the generation of ‘‘gutted’’ ver-
sions of the vectors presented here. Such gutted adenoviral vectors
lack all parts of the viral genome except for the 50 and 30 inverted
terminal repeats and the packaging signal (W) required for replica-
tion and DNA packaging, respectively (Alba et al., 2005). In general,
due to the presence of the inhibitory amiRNA sequences on the
vector, a virus emerging from a recombination between the recom-
binant virus and the wt virus would be attenuated in its replica-
tion. At the same time, such a recombination event would likely
render the ‘‘donor’’ wt virus replication-deﬁcient. Thus, the gener-
ation of a virus that is more dangerous than the parent wt virus
seems unlikely. In any case, this issue would have to be addressed
in animal studies.Such animal studies are also needed to eventually clarify, which
of the 2 RNAi-based approaches, i.e., silencing of adenoviral gene
expression by siRNAs, such as the ones presented in our previous
study (Kneidinger et al., 2012), or by amiRNAs expressed from
and delivered by adenoviral vectors (this study), provide a greater
probability to permit efﬁcient inhibition of adenovirus multiplica-
tion in vivo.5. Conclusion
Taken together, our data indicate that (i) adenoviral vector-
based delivery and expression of amiRNAs can mediate signiﬁcant
gene expression knockdown in cells infected with wt adenovirus;
(ii) targeting of adenoviral pTP mRNA by amiRNA can inhibit the
replication of wt adenovirus in vitro; (iii) efﬁcient inhibition re-
quires a sufﬁciently high intracellular concentration of amiRNA,
which can be achieved by concatemerization of amiRNA hairpins
in primary transcripts; (iv) the intracellular amiRNA concentration
can be further increased upon the encounter of the recombinant
vector with its co-infecting wt counterpart; and (v) amiRNA
expression in cells infected by wt virus and their concomitant
treatment with CDV can result in additive inhibitory effects.
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